1. Merck's shares have declined significantly, increasing its dividend yield and compressing its valuation, presenting an attractive investment opportunity. 2. Keytruda, the company's largest drug, is showing strong revenue growth and potential for further approvals and market expansion. 3. Merck's diverse drug portfolio and robust pipeline support future growth. 4. Merck is trading at a significant discount compared to historical valuations, offering a solid dividend yield and potential for attractive total returns.